GLP-1 RECEPTOR AGONIST
Semaglutide
The same active ingredient as Ozempic and Wegovy, prescribed by licensed providers at a fraction of the cost.
STARTING AT
Save 82% vs brand medications
Free consultation with licensed provider
GLP-1 Medication
Semaglutide
Starting at $179/mo
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist originally developed to treat type 2 diabetes. In clinical trials, researchers discovered it also produced significant weight loss, leading to its FDA approval for chronic weight management under the brand names Wegovy and Ozempic.
GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces after eating. It signals to your brain that you're full, slows digestion, and helps regulate blood sugar levels. Semaglutide mimics this hormone, helping you feel satisfied with less food.
Our compounded semaglutide contains the same active ingredient as brand-name medications but is prepared by licensed 503A compounding pharmacies, making it available at a fraction of the retail cost.
How It Works
Reduces Appetite
Activates GLP-1 receptors in your brain to signal fullness, naturally reducing hunger and cravings.
Slows Digestion
Delays gastric emptying so food stays in your stomach longer, extending satiety between meals.
Stabilizes Blood Sugar
Enhances insulin secretion and reduces glucagon, preventing blood sugar spikes and energy crashes.
STEP Clinical Trials
Proven Results
From landmark FDA-reviewed studies published in the New England Journal of Medicine
15–20%
Average Weight Loss
Percentage of total body weight lost over 68 weeks of treatment
86%
Achieved 5% Loss
Of participants achieved clinically meaningful weight reduction
68
Weeks Studied
Duration of STEP 1 trial with sustained results after 1 year
Results from STEP 1 trial. Individual outcomes vary based on lifestyle, genetics, and medical history.
Treatment Plan
Dosing Schedule
Your dose increases gradually over 5 months to maximize effectiveness while minimizing side effects.
| Month | Weekly Dose | Purpose |
|---|---|---|
| Month 1 | 0.25 mg | Initiation and body adjustment |
| Month 2 | 0.5 mg | First escalation phase |
| Month 3 | 1.0 mg | Therapeutic dose established |
| Month 4 | 1.7 mg | Enhanced effect phase |
| Month 5+ | 2.4 mg | Full maintenance and optimization |
Your provider customizes your dosing based on your individual response, tolerance, and clinical goals.
What to Expect
Common Side Effects
Typically mild and improve within 1–4 weeks as your body adjusts to the medication.
- Nausea
- Constipation
- Diarrhea
- Stomach discomfort
- Decreased appetite
- Mild headache
Rare Side Effects
Uncommon but serious. Contact your provider immediately if you experience these.
- Severe pancreatitis
- Gallbladder complications
- Kidney dysfunction
- Anaphylaxis
- Thyroid concerns
Medical supervision: Your GetSlimRX provider monitors your progress and manages any side effects through secure messaging in your patient portal.
Who Shouldn't Use Semaglutide
- ✕Personal or family history of medullary thyroid carcinoma
- ✕Multiple Endocrine Neoplasia syndrome type 2
- ✕History of pancreatitis or pancreatic disease
- ✕Currently pregnant or breastfeeding
- ✕Planning pregnancy within 2 months
- ✕Advanced kidney disease
- ✕Severe allergic reaction to semaglutide
During your free consultation, our licensed provider will screen for all contraindications and medical interactions to ensure semaglutide is right for you.
Value Comparison
Save 82%
Same active ingredient, dramatically lower cost
Brand Ozempic
$1,000+
/month without insurance
Brand Wegovy
$1,350+
/month without insurance
GetSlimRX
$179
/month — save up to 82%
Frequently Asked Questions
Is compounded semaglutide the same as Ozempic or Wegovy?
How soon will I see results?
Do I give myself injections?
What happens if I have side effects?
Can I use semaglutide long-term?
Do I need insurance to qualify?
Start Your Weight Loss Journey
Our free consultation helps you determine if semaglutide is right for your health goals. Licensed provider review within 24 hours.
No commitment required